Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y, et al. CAR-T treatment for cancer: prospects and challenges. Front Oncol. 2023;13:1288383.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomark Res. 2022;10(1):70.

Article  PubMed  PubMed Central  Google Scholar 

Liu Z, Lei W, Wang H, Liu X, Fu R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp Hematol Oncol. 2024;13(1):22.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55.

Article  PubMed  CAS  Google Scholar 

Zeng W, Zhang P. Resistance and recurrence of malignancies after CAR-T cell therapy. Exp Cell Res. 2022;410(2): 112971.

Article  PubMed  CAS  Google Scholar 

Qu C, Zhang H, Cao H, Tang L, Mo H, Liu F, et al. Tumor buster—where will the CAR-T cell therapy ‘missile’ go? Mol Cancer. 2022;21(1):201.

Article  PubMed  PubMed Central  Google Scholar 

Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146–62.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Freen-van Heeren JJ. Post-transcriptional control of T-cell cytokine production: implications for cancer therapy. Immunology. 2021;164(1):57–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21(1):47–66.

Article  PubMed  Google Scholar 

Lemoine J, Ruella M, Houot R. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing. Clin Cancer Res. 2021;27(23):6298–306.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20(6):1.

Article  Google Scholar 

Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wang L, Zhang L, Dunmall LC, Wang YY, Fan Z, Cheng Z, et al. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors. Cancer Lett. 2024;591: 216871.

Article  PubMed  CAS  Google Scholar 

Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res. 2021;9(1):62.

Article  PubMed  PubMed Central  Google Scholar 

Zhao G, Zhang Y, Xu C-F, Wang J. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles. Sci Bull. 2023;69:354.

Article  Google Scholar 

Zhang R, Han X, Lei Z, Jiang C, Gul I, Hu Q, et al. RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022;150: 106084.

Article  PubMed  CAS  Google Scholar 

Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomark Res. 2023;11(1):49.

Article  PubMed  PubMed Central  Google Scholar 

Mousset CM, Hobo W, Woestenenk R, Preijers F, Dolstra H, van der Waart AB. Comprehensive phenotyping of T cells using flow cytometry. Cytom Part A J Int Soc Anal Cytol. 2019;95(6):647–54.

Article  Google Scholar 

Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity. Nat Cancer. 2023;4(7):968–83.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med. 2017;9(417):1.

Article  Google Scholar 

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492–500.

Article  PubMed  CAS  Google Scholar 

Bulliard Y, Andersson BS, Baysal MA, Damiano J, Tsimberidou AM. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J Hematol Oncol. 2023;16(1):108.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Turtle CJ, Berger C, Sommermeyer D, Hanafi L-A, Pender B, Robinson EM, et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood. 2015;126(23):184.

Article  Google Scholar 

Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy. 2022;24(9):962–73.

Article  PubMed  CAS  Google Scholar 

Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol. 2011;2:36.

Article  PubMed  PubMed Central  Google Scholar 

Konduri V, Joseph SK, Byrd TT, Nawas Z, Vazquez-Perez J, Hofferek CJ, et al. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. Sci Transl Med. 2021;13(592):1.

Article  Google Scholar 

Brandes M, Willimann K, Bioley G, Lévy N, Eberl M, Luo M, et al. Cross-presenting human yδ T cells induce robust CD8+αβ T cell responses. Proc Nat Acad Sci. 2009;106(7):2307–12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, et al. Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia. Front Immunol. 2020;11:1347.

Article  PubMed  PubMed Central  CAS